SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLSD - Clearside BioMedical
CLSD 3.670-5.9%Oct 29 3:47 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: BioHero2/7/2019 1:34:42 PM
   of 17
 
still a mega buying opportunity at this 39 million valuation which is wayy below their cash balance of $65 million .GL

Presentation January 2019

ir.clearsidebio.com

Clearside Biomedical names industry veteran, Dr. Thomas Ciulla, as CMO

biotuesdays.com

Dr. Ciulla has more than 27 years of clinical practice, academic and executive management experience within the global ophthalmic industry. Prior to joining Clearside, he was VP of ophthalmic strategy at Spark Therapeutics, where he led the medical strategy to support development and commercialization of Luxturna, the first FDA-approved gene therapy for a genetic disease.

Before launching his executive management career, Dr. Ciulla co-directed the retina service and ocular angiogenesis research laboratory at Indiana University School of Medicine, the largest U.S. medical school. He also serves on the board of Midwest Eye Institute and is an active member of the Association for Research in Vision and Ophthalmology, Macula and Retina Societies, American Society of Retina Specialists, and the American Academy of Ophthalmology.

Dr. Ciulla also has held numerous leadership roles in more than 100 national clinical trials, including CATT and registration trials for nearly all retinal therapeutics currently approved by the FDA.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext